By Sriparna Roy and Bhanvi Satija (Reuters) -Shares of global vaccine makers were muted on Tuesday as investors and analysts ...

By Sriparna Roy and Bhanvi Satija (Reuters) -Shares of global vaccine makers were mixed on Tuesday, as investors assessed U.S ...

Novavax, Inc. faces profitability challenges despite a promising tech platform, with uncertain revenue streams. Click for my ...

BioNTech won a major shot in the arm for its cancer drug activities last week when Bristol Myers Squibb agreed to pay up to ...

BioNTech is acquiring CureVac in a deal that brings messenger RNA manufacturing capability and cancer immunotherapy ...

The main reason for the downturn in Moderna’s stock is a significant drop in the demand for its COVID-19 vaccine.

Vaccine maker stocks are steady despite RFK Jr.'s decision to fire all members of the CDC expert panel on immunizations. Read ...